NCT04860076View on ClinicalTrials.gov

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

UnknownOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

June 6, 2020

Primary Completion Date

June 6, 2022

Study Completion Date

June 6, 2023

Conditions
MelanomaLung Cancer
Interventions
DRUG

Pembrolizumab

Standard of care

Trial Locations (1)

2650

RECRUITING

Universitair Ziekenhuis Antwerpen, Edegem

Sponsors
All Listed Sponsors
lead

Asylia Diagnostics BV

INDUSTRY

NCT04860076 - Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors | Biotech Hunter | Biotech Hunter